BIOMAT Database Logo BIOMAT Database Logo

Defucosylated mouse‑dog chimeric anti‑HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors. 2022

Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
Department of Molecular Pharmacology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980‑8575, Japan.

Human epidermal growth factor receptor 2 (HER2) overexpression has been reported in various types of cancer, including breast, gastric, lung, colorectal and pancreatic cancer. A humanized anti‑HER2 monoclonal antibody (mAb), trastuzumab, has been shown to improve survival of patients in HER2‑positive breast and gastric cancer. An anti‑HER2 mAb, H2Mab‑77 (mouse IgG1, kappa) was previously developed. In the present study, a defucosylated version of mouse‑dog chimeric anti‑HER2 mAb (H77Bf) was generated. H77Bf possesses a high binding‑affinity [a dissociation constant (KD): 7.5x10‑10 M, as determined by flow cytometric analysis] for dog HER2‑overexpressed CHO‑K1 (CHO/dHER2) cells. H77Bf highly exerted antibody‑dependent cellular cytotoxicity (ADCC) and complement‑dependent cytotoxicity (CDC) for CHO/dHER2 cells by canine mononuclear cells and complement, respectively. Moreover, administration of H77Bf significantly suppressed the development of CHO/dHER2 xenograft tumor in mice compared with the control dog IgG. H77Bf also possesses a high binding‑affinity (KD: 7.2x10‑10 M) for a canine mammary gland tumor cell line (SNP), and showed high ADCC and CDC activities for SNP cells. Intraperitoneal administration of H77Bf in mouse xenograft models of SNP significantly suppressed the development of SNP xenograft tumors compared with the control dog IgG. These results indicated that H77Bf exerts antitumor activities against dHER2‑positive canine cancers, and could be valuable treatment regimen for canine cancers.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000920 Antibody-Dependent Cell Cytotoxicity The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. ADCC,Cytotoxicity, Antibody-Dependent Cell,Cell Cytoxicity, Antibody-Dependent,Antibody Dependent Cell Cytotoxicity,Antibody-Dependent Cell Cytotoxicities,Antibody-Dependent Cell Cytoxicities,Antibody-Dependent Cell Cytoxicity,Cell Cytotoxicities, Antibody-Dependent,Cell Cytotoxicity, Antibody-Dependent,Cell Cytoxicities, Antibody-Dependent,Cell Cytoxicity, Antibody Dependent,Cytotoxicities, Antibody-Dependent Cell,Cytotoxicity, Antibody Dependent Cell,Cytoxicities, Antibody-Dependent Cell,Cytoxicity, Antibody-Dependent Cell
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
March 2019, Biochemistry and biophysics reports,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
An Anti-HER2 Monoclonal Antibody H2Mab-41 Exerts Antitumor Activities in Mouse Xenograft Model Using Dog HER2-Overexpressed Cells.
August 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 134-mG2a-f Exerts Antitumor Activities in Mouse Xenograft Models of Dog Epidermal Growth Factor Receptor-Overexpressed Cells.
August 2021, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.
April 2020, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
November 2020, Oncology reports,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
A defucosylated anti-PD-L1 monoclonal antibody 13-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
December 2020, Biochemistry and biophysics reports,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.
July 2021, Oncology reports,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
October 2020, International journal of molecular medicine,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma.
December 2020, Biochemistry and biophysics reports,
Hiroyuki Suzuki, and Tomokazu Ohishi, and Teizo Asano, and Tomohiro Tanaka, and Masaki Saito, and Takuya Mizuno, and Takeo Yoshikawa, and Manabu Kawada, and Mika K Kaneko, and Yukinari Kato
Anti-CD133 Monoclonal Antibody CMab-43 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer.
April 2019, Monoclonal antibodies in immunodiagnosis and immunotherapy,
Copied contents to your clipboard!